Home
Forms Library
Entyvio (Vedolizumab) Order Form - ARJ Infusion Services

Entyvio (Vedolizumab) Order Form - ARJ Infusion Services 2025

Entyvio (Vedolizumab) Order Form - ARJ Infusion Services Preview on Page 1

See details

4.1 out of 5

39 votes

The document is a provider order form for Vedolizumab (Entyvio), detailing patient and provider information, therapy administration procedures, nursing care requirements, laboratory orders, pre-medication instructions, and fax numbers for various locations. It outlines the treatment protocol including dosage, frequency of administration, and necessary precautions regarding patient health status.

Here's how it works

01. Edit your form online

Type text, add images, blackout confidential details, add comments, highlights and more.

02. Sign it in a few clicks

Draw your signature, type it, upload its image, or use your mobile device as a signature pad.

03. Share your form with others

Send it via email, link, or fax. You can also download it, export it or print it out.

The best way to edit Entyvio (Vedolizumab) Order Form - ARJ Infusion Services in PDF format online

Ease of Setup

DocHub User Ratings on G2

Ease of Use

DocHub User Ratings on G2

Adjusting paperwork with our feature-rich and intuitive PDF editor is easy. Make the steps below to fill out Entyvio (Vedolizumab) Order Form - ARJ Infusion Services online quickly and easily:

Sign in to your account. Log in with your email and password or register a free account to try the product prior to upgrading the subscription.
Upload a document. Drag and drop the file from your device or import it from other services, like Google Drive, OneDrive, Dropbox, or an external link.
Edit Entyvio (Vedolizumab) Order Form - ARJ Infusion Services. Quickly add and underline text, insert images, checkmarks, and symbols, drop new fillable fields, and rearrange or remove pages from your document.
Get the Entyvio (Vedolizumab) Order Form - ARJ Infusion Services completed. Download your adjusted document, export it to the cloud, print it from the editor, or share it with other participants using a Shareable link or as an email attachment.

Benefit from DocHub, the most straightforward editor to rapidly handle your documentation online!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.

Is Entyvio a high risk medication?

1.2 Vedolizumab should be given until it stops working or surgery is needed. At 12 months after the start of treatment, people should be reassessed to see whether treatment should continue. Treatment should only continue if there is clear evidence of ongoing clinical benefit.

What is the generic name for vedolizumab?

ENTYVIO (vedolizumab) for Ulcerative Colitis and Crohns Disease.

What does Entyvio infusion do?

Entyvio is a brand of vedolizumab. This injection treats ulcerative colitis and Crohns disease. A healthcare provider will give you this medication in a hospital or clinic setting.

Is vedolizumab an infusion or injection?

Vedolizumab injection comes as a powder to be mixed with sterile water and injected intravenously (into a vein) over 30 minutes by a doctor or nurse. It is usually given in a doctors office once every 2 to 8 weeks, more often in the beginning of your treatment and less often as your treatment continues.

Is vedolizumab a chemo drug?

In rare cases, Entyvio can cause severe, life-threatening infections, anaphylaxis, or liver problems. Before starting Entyvio, talk with your healthcare provider about the risks and benefits of this medication.

What is the schedule for vedolizumab?

The recommended dose regimen of intravenous vedolizumab is 300 mg administered by intravenous infusion at 0, 2 and 6 weeks and then every 8 weeks thereafter. Therapy for patients with ulcerative colitis should be discontinued if no evidence of therapeutic benefit is observed by week 10 (see section 5.1).

Is vedolizumab the same as Entyvio?

Vedolizumab (Entyvio) is an integrin receptor antagonist indicated for the treatment of adult patients with moderately to severely active Crohns disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a tumour necrosis factor (TNF) alpha antagonist; or who have had

Entyvio (Vedolizumab) Order Form - ARJ Infusion Services 2025

Here's how it works